You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥-B(01672.HK):腫瘤脂質代謝與口服檢查點抑制劑研發投資升級
格隆匯 03-30 08:55

格隆匯 3 月 30日丨歌禮制藥-B(01672.HK)發佈公吿,董事會已決議通過投入更多資源及投資於腫瘤脂質代謝與口服檢查點抑制劑方面的研發,該方面的產品管線如下圖所示:

董事會認為公司已於過去數年透過許可及內部研發於腫瘤脂質代謝及口服PD-L1小分子抑制劑方面作出巨大努力並取得顯著進展,為公司的腫瘤產品管線的未來發展奠定堅實的基礎,因此提高投入符合公司及其股東的整體最佳利益。董事會將繼續監督公司產品管線的開發,並考慮在有需要時採取合適行動,包括但不限於變更所得款項用途。

此外,由研究者發起、在美國完成的ASC40 (TVB-2640)聯合貝伐珠單抗治療高級別星形細胞瘤首次復發患者的II期臨牀試驗取得積極結果。公司計劃在中國啟動ASC40 (TVB-2640)聯合貝伐珠單抗的隨機、雙盲、安慰劑對照的關鍵性II期臨牀試驗,試驗人羣與美國試驗患者人羣相同(高級別星形細胞瘤首次復發患者)。

除了以FASN為靶點的腫瘤脂質代謝候選藥物外,公司自主研發的口服PD-L1小分子抑制劑在動物模型中的抗腫瘤活性較已上市的一款抗PD-L1抗體有潛在優勢。公司相信,口服PD-L1小分子抑制劑是腫瘤免疫治療的新一代檢查點抑制劑,而且具有與口服FASN小分子抑制劑聯合使用的潛力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account